跳转至内容
Merck
CN

1005004

USP

乙酰唑胺

United States Pharmacopeia (USP) Reference Standard

别名:

5-乙酰胺基-1,3,4-噻二唑-2-磺酰胺, N-(5-[氨基磺酰基]-1,3,4-噻二唑-2-基)乙酰胺, N-(5-氨磺酰基-1,3,4-噻二唑-2-基)乙酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C4H6N4O3S2
CAS号:
分子量:
222.25
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

acetazolamide

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

CC(=O)Nc1nnc(s1)S(N)(=O)=O

InChI

1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)

InChI key

BZKPWHYZMXOIDC-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Acetazolamide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Acetazolamide Compounded Oral Suspension
  • Acetazolamide Extended-Release Capsules
  • Acetazolamide for Injection
  • Acetazolamide Tablets
碳酸酐酶抑制剂;增加脑血流量。

生化/生理作用

通过与水通道蛋白相互作用抑制膜的水渗透性

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2 - Skin Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

W G Reiss et al.
The Annals of pharmacotherapy, 30(5), 514-519 (1996-05-01)
To summarize the pharmacology, pharmacokinetics, efficacy, and safety of acetazolamide and to evaluate its therapeutic role in patients with epilepsy. A computerized search of the MEDLINE (OVID) database (1966-1994) was used to identify publications regarding acetazolamide. The MEDLINE search was
Emma V Low et al.
BMJ (Clinical research ed.), 345, e6779-e6779 (2012-10-20)
To assess the efficacy of three different daily doses of acetazolamide in the prevention of acute mountain sickness and to determine the lowest effective dose. Systematic review and meta-analysis. Medline and Embase along with a hand search of selected bibliographies.
Bengt Kayser et al.
High altitude medicine & biology, 13(2), 82-92 (2012-06-26)
Acetazolamide is used to prevent acute mountain sickness (AMS). We assessed efficacy and harm of acetazolamide for the prevention of AMS, and tested for dose-responsiveness. We systematically searched electronic databases (until April 2011) for randomized trials comparing acetazolamide with placebo
Neil D Ritchie et al.
Journal of travel medicine, 19(5), 298-307 (2012-09-05)
Acetazolamide has been reported to be effective in the prevention of acute mountain sickness (AMS). Our aim was to conduct a systematic review of randomized, placebo-controlled trials of acetazolamide in the prevention of AMS. Studies were identified by searching the
A S Vagal et al.
AJNR. American journal of neuroradiology, 30(5), 876-884 (2009-02-28)
The acetazolamide (ACZ) challenge test is a useful clinical tool and a reliable predictor of critically reduced perfusion. In patients with chronic steno-occlusive disease, the ability to maintain normal cerebral blood flow by reducing vascular resistance secondary to autoregulatory vasodilation

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门